Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides

Blood

Volumn 90, Issue 1, 1997, Pages 331-339

  Vaerman, J L ^a   Moureau, P ^a   Deldime, F ^a   Lewalle, P ^a   Lammineur, C ^a   Morschhauser, F ^a   Martiat, P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DEOXYADENOSINE PHOSPHATE; DEOXYCYTIDINE PHOSPHATE; DEOXYGUANOSINE PHOSPHATE; DEOXYRIBONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; THYMIDINE PHOSPHATE;

ARTICLE; BONE MARROW CELL; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

EID: 0030974489     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.331     Document Type: Article

References (63)

1. Woolf TM, Melton DA, Jennings CGB: Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 89:7305, 1992
2. Stein CA, Krieg AM: Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 3:67, 1994
3. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333, 1994
4. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents -is the bullet really magical? Science 261:1004, 1993
5. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano D, Tokunaga T: Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. J Immunol 148:4072, 1992
6. Kuramoto E, Yano O, Kimura Y, Baba U, Makino T, Yamamoto S, Yamamoto T, Kataoka T, Tokunaga T: Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res 83:1128, 1992
7. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L: Aptameric inhibition of p210 bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 22:2150, 1994
8. Bergan R, Kyle E, Connell Y, Neckers L: Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res Dev 5:33, 1995
9. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355:564, 1992
10. Yakubov L, Khaled Z, Zhang LM, Truneh A, Vlassov V, Stein CA: Mode of interaction of oligodeoxynucleotides with recombinant sCD4. J Biol Chem 268:18818, 1993
11. Stein CA, Cleary A, Yakubov L, Lederman S: Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of HIV-1 gp120. Antisense Res Dev 3:19, 1993
12. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martial P: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86:3891, 1995
13. Taj AS, Martiat P, Dhut S, Chaplin D, Dowding C, Th'ng KH, Goldstein I, Daley GQ, Goldman JM: Inhibition of P210 BCR-ABL expression in K562 cells by electroporation with an antisense oligonucleotide. Leuk Lymphoma 3:201, 1990
14. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562, 1991
15. Skorski T, Szczylik C, Malaguarnera L, Calabretta B: Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem Cytobiol 29:85, 1991
16. Mahon FX, Belloc F, Reiffers J: Antisense oligomers in chronic myeloid leukaemia. Lancet 341:566, 1993
17. Kirkland MA, O'Brien SG, McDonald C, Davidson RJ, Cross NCP, Goldman JM: BCR-ABL antisense purging in chronic myeloid leukaemia. Lancet 342:614, 1993
18. Maekawa T, Murakami A, Kimura S, Inazawa J, Hirakawa K, Abe T, Makino K: Clonal suppression of human leukemia cell growth by antisense oligodeoxynucleotide phosphorothioates. J Cell Biochem 17E:197, 1993 (suppl)
19. Skorski T, Nieborowska Skorska M, Barletta C, Malaguarnera L, Szczylik C, Chen ST, Lange B, Calabretta B: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 92:194, 1993
20. Vaerman JL, Lewalle P, Martiat P: Antisense inhibition of p210 bcr-abl in chronic myeloid leukemia. Slem Cells 11:89, 1993 (suppl 3)
21. De Fabritiis P, Amadori S, Calabretta B, Mandelli F: Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 12:261, 1993
22. Smetsers TFCM, Skorski T, Van de Locht LTF, Wessels HMC, Pennings AHM, De Witte T, Calabretta B, Mensink EJBM: Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome positive cell line BV173. Leukemia 1:129, 1994
23. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, lozzo RV, Zon G, Calabretta B: Suppression of Philadelphia leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:4504, 1994
24. Okabe M, Kunieda Y, Miyagishima T, Kobayashi M, Kurosawa M, Itaya T, Sakurada K, Miyazaki T: BCR-ABL oncoprotein-targeted antitumor activity of antisense oligonucleotides complementary to BCR/ABL mRNA and Herbimycin A, an antagonist of protein tyrosine kinase: Inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformative cells. Leuk Lymphoma 10:307, 1993
25. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038, 1994
26. Thomas M, Kosciolek B, Wang N, Rowley P: Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines. Leuk Res 18:401, 1994
27. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
28. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein G: Liposomal delivery of methylphosphonate antisense oligonucleotides in chronic myelogenous leukemia. Blood 84:601, 1995
29. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM: Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8:2156, 1994
30. Smetsers TFCM, van de Locht LTF, Pennings AHM, Wessels HMC, de Witte TM, Mensink EJBM: Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 9:118, 1995
31. Mahon FX, Ripoche J, Piegonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J: Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 23:1606, 1995
32. de Fabritiis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F: In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 9:662, 1995
33. Nichols GL: Antisense oligodeoxynucleotides as therapeutic agents for chronic myelogenous leukemia. Antisense Res Dev 5:67, 1995
34. de Klein A, Geurts van Kessel A, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr N, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300:765, 1982
35. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcripts of abl and bcr genes in chronic myeloid leukemia. Nature 315:550, 1985
36. Konopka JB, Watanabe SM, Witte ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035, 1984
37. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
38. Elefanty AG, Cory S: Bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple hematologic neoplasms in mice. EMBO J 9:1069, 1990
39. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J: Acute leukemia in bcr-abl transgenic mice. Nature 344:251, 1990
40. Vaerman JL, Moureau P, Larondelle Y, Martiat P, Philippe M: Prediction of oligodeoxyribonucleotides eluting salt conditions on anion exchange column. Nucleic Acids Res 20:3522, 1992
41. Pegorado L, Matera L, Ritz J, Levis A, Palumbo A, Biagini G: Establishment of a Ph1 positive human cell line (BV173). J Natl Cancer Inst 70:447, 1983
42. Martiat P, Maisin D, Philippe M, Ferrant A, Michaux JL, Cassiman JJ, Van den Berghe H, Sokal G: Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction with nested primers. Br J Haematol 75:355, 1990
43. Wickstrom E: Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 13:97, 1986
44. Eder PS, DeVine RJ, Dagle JM, Walder JA: Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1:141, 1991
45. Pompon A, Lefebvre I, Imbach JL: On-line internal surface reverse-phase cleaning: The direct HPLC analysis of crude biological samples. Application to the kinetics of degradation of oligonucleotides in cell culture medium. Biochem Pharmacol 43:1769, 1992
46. Fisher TL, Terhorst T, Cao X, Wagner RW: Intracellular disposition and metabolism of fluorescently labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res 21:3857, 1993
47. Vichier-Guerre S, Pompon A, Levebvre I, Imbach JL: New insights into the resistance of α-oligonucleotides to nucleases. Antisense Res Dev 4:9, 1994
48. Spitzer F, Eckstein F: Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucleic Acids Res 16:11691, 1988
49. Milligan J, Matteucci M, Martin J: Current concepts in antisense drug design. J Med Chem 36:1923, 1993
50. Theiss JC, Morris NR, Fischer GA: Pyrimidine nucleotide metabolism in L5178Y murine leukemia cells: Deoxycytidine protection from deoxyguanosine toxicity. Cancer Biochem Biophys 1:211, 1976
51. Fox RM, Tripp EH, Tattersall MHN: Mechanism of deoxycytidine rescue of thymidine toxicity in human T-leukemic lymphocytes. Cancer Res 40:1718, 1980
52. Wilkinson YA, McKenna PG: The effects of thymidine on deoxyribonucleotide pool level, cytotoxicity and mutation induction in Friend Mouse erythroleukaemia cells. Leuk Res 13:615, 1989
53. Tattersall MHN, Slowiaczek P, De Fazio A: Regional variation in human extracellular purine levels. J Lab Clin Med 102:411, 1983
54. Tanaka Y, Yoshihara K, Tsuyuki M, Kamiya T: Apoptosis induced by adenosine in human leukemia HL-60 cells. Exp Cell Res 213:242, 1994
55. Fox RM, Kefford RF, Tripp EH, Taylor IW: G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine. Cancer Res 41:5141, 1981
56. Ross DD, Akman SA, Schrecker AW, Bachur NR: Effects of deoxynucleosides on cultured human leukemia cell growth and deoxynucleotide pools. Cancer Res 41:4493, 1981
57. Kefford RF, Fox RM: Purine deoxynucleoside toxicity in nondividing human lymphoid cells. Cancer Res 42:324, 1982
58. De Fouw NJ, Ma DDF, Michalevicz R, Gray DA, Hoffbrand AV: Differential cytotoxicity of deoxyguanosine and 8-aminoguanosine for human leukemic cell lines and normal bone marrow progenitor cells. Hematol Oncol 2:189, 1984
59. Russel NH, Hoffbrand AV, Bellingham AJ: Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow. Leuk Res 10:325, 1986
60. Gilles RV, Spiller DG, Green JA, Clark RE, Tidd DM: Optimisation of antisense oligodeoxynucleotides structure for targeting bcr-abl mRNA. Blood 86:744, 1995
61. Spiller DG, Tidd DM: Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res Dev 5:13, 1995
62. Giles RV, Spiller DG, Tidd DM: Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 5:23, 1995
63. Giles RV, Ruddell CJ, Spiller DG, Green JA, Tidd DM: Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res 23:954, 1995